Log in
NASDAQ:QTNT

Quotient Stock Forecast, Price & News

$5.66
+0.01 (+0.18 %)
(As of 09/18/2020 09:37 PM ET)
Add
Compare
Today's Range
$5.55
Now: $5.66
$5.84
50-Day Range
$4.38
MA: $5.93
$8.16
52-Week Range
$2.39
Now: $5.66
$10.38
Volume3.23 million shs
Average Volume849,730 shs
Market Capitalization$456.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Read More
Quotient logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.11 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTNT
CUSIPN/A
Phone011-41-22-716-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.66 million
Book Value($0.07) per share

Profitability

Net Income$-102,770,000.00
Net Margins-313.16%

Miscellaneous

EmployeesN/A
Market Cap$456.44 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$5.66
+0.01 (+0.18 %)
(As of 09/18/2020 09:37 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quotient (NASDAQ:QTNT) Frequently Asked Questions

How has Quotient's stock been impacted by COVID-19?

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, QTNT stock has increased by 22.0% and is now trading at $5.66.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Quotient?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quotient
.

When is Quotient's next earnings date?

Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Quotient
.

How were Quotient's earnings last quarter?

Quotient Ltd (NASDAQ:QTNT) posted its earnings results on Monday, August, 3rd. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.01. The firm had revenue of $8.92 million for the quarter, compared to analysts' expectations of $8.50 million.
View Quotient's earnings history
.

What guidance has Quotient issued on next quarter's earnings?

Quotient issued an update on its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million.

What price target have analysts set for QTNT?

1 brokerages have issued 12 month price objectives for Quotient's shares. Their forecasts range from $13.50 to $13.50. On average, they expect Quotient's share price to reach $13.50 in the next year. This suggests a possible upside of 138.5% from the stock's current price.
View analysts' price targets for Quotient
.

Who are some of Quotient's key competitors?

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Novavax (NVAX), Micron Technology (MU) and Ocular Therapeutix (OCUL).

Who are Quotient's key executives?

Quotient's management team includes the following people:
  • Mr. Franz Walt, CEO & Director (Age 60)
  • Mr. Jeremy Stackawitz, Pres (Age 44)
  • Mr. Edward Farrell, Pres (Age 49)
  • Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
  • Mr. John Allan, Corp. Sr. VP & CTO

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (3.60%), TimesSquare Capital Management LLC (3.46%), Hudson Bay Capital Management LP (1.89%), Bellevue Group AG (0.74%), Gilder Gagnon Howe & Co. LLC (0.51%) and Tekla Capital Management LLC (0.51%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient
.

Which major investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Gilder Gagnon Howe & Co. LLC, TimesSquare Capital Management LLC, Two Sigma Advisers LP, DAVENPORT & Co LLC, Sei Investments Co., Swiss National Bank, and Arizona State Retirement System. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, and Jeremy Stackawitz.
View insider buying and selling activity for Quotient
.

Which major investors are buying Quotient stock?

QTNT stock was purchased by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Nuveen Asset Management LLC, Acuitas Investments LLC, Bellevue Group AG, Tekla Capital Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Roubaix Capital LLC. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient
.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $5.66.

How big of a company is Quotient?

Quotient has a market capitalization of $456.44 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

What is Quotient's official website?

The official website for Quotient is www.quotientbd.com.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.